

**PATENT APPLICATION**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Application No.: New U.S. Patent Application

Filed: December 21, 2001

Docket No.: 109993

For: GENE THERAPY USING ANTI-GP41 ANTIBODY AND CD4 IMMUNOADHESIN

**PRELIMINARY AMENDMENT**

Director of the U.S. Patent and Trademark Office  
Washington, D. C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

**IN THE CLAIMS:**

Please replace claims 15-16 as follows:


15. (Amended) A host cell which comprises at least an expression cassette  
of claim 2.
16. (Amended) A host cell which comprises at least a vector of claim 4.

**REMARKS**

Claims 1 - 38 are pending. By this Preliminary Amendment, claims 15-16 are amended to remove multiple dependencies. Prompt and favorable examination on the merits is respectfully requested.

The attached Appendix includes marked-up copies of each rewritten claim (37 C.F.R. 1.121(c)(1)(ii)).

Respectfully submitted,



William P. Berridge  
Registration No. 30,024

Melanie L. Mealy  
Registration No. 40,085

WPB:MLM/mlb  
Attached: Appendix  
Date: December 21, 2001

**OLIFF & BERRIDGE, PLC**  
**P.O. Box 19928**  
**Alexandria, Virginia 22320**  
**Telephone: (703) 836-6400**

DEPOSIT ACCOUNT USE AUTHORIZATION Please grant any extension necessary for entry; Charge any fee due to our Deposit Account No. 15-0461
--

•

### Changes to Claims:

The following are marked-up versions of the amended claims:

15. (Amended) A host cell which comprises at least an expression cassette selected among the group consisting of an expression cassette of claim 2, the first expression cassette of claim 3 and the second expression cassette of claim 3.

16. (Amended) A host cell which comprises at least a vector ~~selected among the group consisting of a vector of claim 4, the first vector of claim 3 and the second vector of claim 3.~~